- The FDA has cleared Baxter International's (NYSE:BAX) next-generation Artificial Kidney 98 (AK 98) dialysis machine, a portable and easy-to-use system to administer hemodialysis (HD) treatments.
- AK 98 offers encrypted, two-way connectivity, which enables the system to pull prescriptions directly from the electronic medical record for simplified workflow and data handling.
- AK 98 offers several key features to help dialysis providers efficiently manage HD treatment sessions, including:
- Automatic Alert Resolution, which enables the machine to self-clear already corrected pressure alarms and avoid unnecessary stoppage of treatment.
- An user interface with app-like functionality designed to simplify prescription management and treatment supervision.
- A fast, simple set-up process allowing for greater flexibility and utilization of staff time and resources, and;
- A stable base design that allows for easy concentrate or portable reverse osmosis storage and transport with the machine.